| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.0078 | 0.9 |